Evolution of fibrinogen-coated collagen patch for use as a topical hemostatic agent
✍ Scribed by Deha Erdogan; Thomas M. van Gulik
- Publisher
- John Wiley and Sons
- Year
- 2008
- Tongue
- English
- Weight
- 284 KB
- Volume
- 85B
- Category
- Article
- ISSN
- 1552-4973
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
Human fibrinogen and thrombin have been combined and coated onto a collagen patch for use as a topical hemostatic agent. These agents have now been used for many years to induce rapid hemostasis and tissue sealing after various indications including thoracic‐, plastic‐, pediatric‐, liver‐, and minimally invasive surgery. The only ready‐to‐use fibrinogen‐coated collagen patch at this moment, the third‐generation surgical patch (SP‐3), contains no bovine aprotinin (antifibrinolytic protein) in contrast to its precursor SP‐2, and is thus devoid of bovine‐derived components. In vitro studies have shown equal bioequivalence between SP‐2 and SP‐3. Various experiments in animal models under normal, stressful, and hyperfibrinolytic conditions showed that SP‐3 has comparable tissue sealing properties and also outperformed fibrin sealants alone in some studies. The results from these pre‐clinical bridging studies showed that aprotinin is not essential for the therapeutic efficacy of SP‐3. In conclusion, SP‐3 has evolved into a rapid, ready‐to‐use adjunct to primary measures for tissue sealing and hemostasis, suitable in cardiovascular‐, thoracic‐, neuro‐, spleen‐, kidney‐, and liver‐surgery. © 2007 Wiley Periodicals, Inc. J Biomed Mater Res Part B: Appl Biomater, 2008